CD138- plasma cell myeloma
(Source: Blood)
Source: Blood - September 11, 2019 Category: Hematology Authors: Shuai, W., Li, S. Tags: Free Research Articles, BloodWork, Lymphoid Neoplasia BLOOD WORK Source Type: research

Natural history and cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL
(Source: Blood)
Source: Blood - September 11, 2019 Category: Hematology Authors: Bueno, C., Tejedor, J. R., Bashford-Rogers, R., Gonzalez-Silva, L., Valdes-Mas, R., Agraz-Doblas, A., Diaz de la Guardia, R., Ribera, J., Zamora, L., Bilhou-Nabera, C., Abermil, N., Guermouche, H., Gouache, E., Leverger, G., Fraga, M. F., Fernandez, A. F. Tags: Lymphoid Neoplasia Letter to Blood Source Type: research

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
The use of anti-thymocyte globulin (ATG) has represented the standard of care in graft-versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated donor (MMUD) transplant. The safety and feasibility of posttransplant cyclophosphamide (PTCY) in this setting have been reported recently, but no study has compared the outcomes of PTCY vs ATG in 9/10 MMUD transplants. Using the registry data of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we performed a matched-pair analysis comparing those 2 strategies in a 9/10 MMUD setting. Ninety-three patients recei...
Source: Blood - September 11, 2019 Category: Hematology Authors: Battipaglia, G., Labopin, M., Kröger, N., Vitek, A., Afanasyev, B., Hilgendorf, I., Schetelig, J., Ganser, A., Blaise, D., Itälä-Remes, M., Passweg, J. R., Bonifazi, F., Finke, J., Ruggeri, A., Nagler, A., Mohty, M. Tags: Transplantation, Myeloid Neoplasia, Clinical Trials and Observations Source Type: research

Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients
In this study, we aim to describe the genetic determinants that modify the FVIII PK profile in a population of 43 pediatric hemophilia A patients. We observed that VWF:Ag and VWF propeptide (VWFpp)/VWF:Ag, but not VWFpp, were associated with FVIII half-life. VWFpp/VWF:Ag negatively correlated with FVIII half-life in patients with non-O blood type, but no correlation was observed for type O patients, suggesting that von Willebrand factor (VWF) half-life, as modified by the ABO blood group, is a strong regulator of FVIII PK. The FVIII-binding activity of VWF positively correlated with FVIII half-life, and the rare or low-fre...
Source: Blood - September 11, 2019 Category: Hematology Authors: Swystun, L. L., Ogiwara, K., Rawley, O., Brown, C., Georgescu, I., Hopman, W., Labarque, V., Male, C., Thom, K., Blanchette, V. S., Carcao, M. D., Lillicrap, D. Tags: Thrombosis and Hemostasis Source Type: research

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
In conclusion, these groups of diseases represent a continuum of related diseases rather than discrete diagnostic entities. (Source: Blood)
Source: Blood - September 11, 2019 Category: Hematology Authors: Zhang, H., Wilmot, B., Bottomly, D., Dao, K.-H. T., Stevens, E., Eide, C. A., Khanna, V., Rofelty, A., Savage, S., Reister Schultz, A., Long, N., White, L., Carlos, A., Henson, R., Lin, C., Searles, R., Collins, R. H., DeAngelo, D. J., Deininger, M. W., D Tags: Myeloid Neoplasia Source Type: research

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involvement, due to strict eligibility criteria. Here, we report on our institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel. No patient experienced greater than grade 1 neurotoxicity, and no patient required tocilizumab or steroids for CAR T-cell–mediated toxicities. Biomarke...
Source: Blood - September 11, 2019 Category: Hematology Authors: Frigault, M. J., Dietrich, J., Martinez-Lage, M., Leick, M., Choi, B. D., DeFilipp, Z., Chen, Y.-B., Abramson, J., Crombie, J., Armand, P., Nayak, L., Panzini, C., Riley, L. S., Gallagher, K., Maus, M. V. Tags: Immunobiology and Immunotherapy, Lymphoid Neoplasia, Brief Reports, Clinical Trials and Observations Source Type: research

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily or 160 mg twice daily. Part 2 (expansion) consisted of disease-specific cohorts, including treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The primary end points were safety and tolerability, and definition of the maximum tolerated dose (part 1). Additional end points inc...
Source: Blood - September 11, 2019 Category: Hematology Authors: Tam, C. S., Trotman, J., Opat, S., Burger, J. A., Cull, G., Gottlieb, D., Harrup, R., Johnston, P. B., Marlton, P., Munoz, J., Seymour, J. F., Simpson, D., Tedeschi, A., Elstrom, R., Yu, Y., Tang, Z., Han, L., Huang, J., Novotny, W., Wang, L., Roberts, A. Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research

PTCY keeps on giving!
(Source: Blood)
Source: Blood - September 11, 2019 Category: Hematology Authors: Radojcic, V., Luznik, L. Tags: Free Research Articles COMMENTS Source Type: research

Illuminating neutrophilic myeloid neoplasms
(Source: Blood)
Source: Blood - September 11, 2019 Category: Hematology Authors: Hasserjian, R. P. Tags: Free Research Articles COMMENTS Source Type: research

The CNS can be a safe space for CARs
(Source: Blood)
Source: Blood - September 11, 2019 Category: Hematology Authors: Ramos, C. A. Tags: Free Research Articles COMMENTS Source Type: research

Garcia-Carmona Y, Cols M, Ting AT, et al. Differential induction of plasma cells by isoforms of human TACI. Blood. 2015;125(11):1749-1758.
(Source: Blood)
Source: Blood - September 4, 2019 Category: Hematology Tags: Free Research Articles ERRATUM Source Type: research

Triple hit B-cell lymphoma with diffuse kidney involvement sparing the glomeruli
(Source: Blood)
Source: Blood - September 4, 2019 Category: Hematology Authors: Ali, N. D., Bains, A. Tags: Free Research Articles, BloodWork, Lymphoid Neoplasia BLOOD WORK Source Type: research

Fungal spore contamination mimicking parasitic infection
(Source: Blood)
Source: Blood - September 4, 2019 Category: Hematology Authors: Blum, S., Cairoli, A. Tags: Free Research Articles, BloodWork BLOOD WORK Source Type: research

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness
(Source: Blood)
Source: Blood - September 4, 2019 Category: Hematology Authors: Munawar, U., Rasche, L., Müller, N., Vogt, C., Da-Via, M., Haertle, L., Arampatzi, P., Dietrich, S., Roth, M., Garitano-Trojaola, A., Steinhardt, M. J., Strifler, S., Gallardo, M., Martinez-Lopez, J., Bargou, R. C., Heckel, T., Einsele, H., Stu&#x Tags: Multiple Myeloma, Lymphoid Neoplasia Letter to Blood Source Type: research

Shared roles for Scl and Lyl1 in murine platelet production and function
The stem cell leukemia (Scl or Tal1) protein forms part of a multimeric transcription factor complex required for normal megakaryopoiesis. However, unlike other members of this complex such as Gata1, Fli1, and Runx1, mutations of Scl have not been observed as a cause of inherited thrombocytopenia. We postulated that functional redundancy with its closely related family member, lymphoblastic leukemia 1 (Lyl1) might explain this observation. To determine whether Lyl1 can substitute for Scl in megakaryopoiesis, we examined the platelet phenotype of mice lacking 1 or both factors in megakaryocytes. Conditional Scl knockout (KO...
Source: Blood - September 4, 2019 Category: Hematology Authors: Chiu, S. K., Orive, S. L., Moon, M. J., Saw, J., Ellis, S., Kile, B. T., Huang, Y., Chacon, D., Pimanda, J. E., Beck, D., Hamilton, J. R., Tremblay, C. S., Curtis, D. J. Tags: Platelets and Thrombopoiesis Source Type: research